Robert W. Baird analyst Jack Allen has maintained their bullish stance on VOR stock, giving a Buy rating yesterday.
Jack Allen has given his Buy rating due to a combination of factors related to Vor Biopharma’s promising clinical progress and strategic positioning in the market. Vor’s recent first quarter financial report showed consistency with expectations and included updates on their pipeline that signal strong enrollment in ongoing studies. This momentum is particularly evident with multiple patients now treated with their leading therapy candidates, which suggests growing enthusiasm and confidence from investigators in the studies.
Furthermore, the planned clinical updates in the second half of the year are highly anticipated to provide a more comprehensive dataset from ongoing trials, which could potentially highlight the efficacy of Vor’s therapies. The gradual dose escalation and expansion of their trem-cel study to include additional patient groups, combined with the quick progress of the VCAR33 program, underpin Allen’s optimism. He also cites Vor’s sufficient cash runway, which is expected to support operations well into the second half of 2025, as a financial stabilizer that allows for the continued development of their therapeutic programs without immediate capital concerns. These elements collectively reinforce Allen’s positive outlook and Buy rating for Vor Biopharma.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $12.00 price target.
VOR’s price has also changed slightly for the past six months – from $1.760 to $1.710, which is a -2.84% drop .
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Vor Biopharma (VOR) Company Description:
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies.
Read More on VOR:
- Vor Bio price target lowered to $10 from $15 at Oppenheimer
- Vor Bio reports Q1 EPS (45c), consensus (38c)
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Vor Biopharma Welcomes Oncology Expert to Board of Directors
- Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
